[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hiv-associate-weight-loss\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hiv-associate-weight-loss":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":34,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100562396","phase-4-change-in-body-weight-and-bmi-in-pwh-with-dor3tctdf-compared-with-insti-100562396",false,"NCT06602622","Change in Body Weight and BMI in PWH with DOR\u002F3TC\u002FTDF Compared with INSTI","Change in Body Weight and BMI in PWH Virologically Suppressed Who Maintain a Second-generation INSTI Regimen Compared to Those Who Switch to DOR\u002F3TC\u002FTDF At 48 Weeks","TLATOANI","Inclusion Criteria:\n\n1. Virologically suppressed for at least 48 weeks prior to study entry\n2. Coming from a regimen containing Bictegravir\u002FEmtricitabine\u002FTenofovir Alafenamide (BIC\u002FFTC\u002FTAF), Dolutegravir\u002FLamivudine\u002FAbacavir (DTG\u002F3TC\u002FABC), or, Dolutegravir\u002FTenofovir Disoproxil Fumarate\u002FEmtricitabine (DTG+TDF\u002FFTC) with no known failures to integrase inhibitors for al least 48 weeks.\n3. BMI ≥25 kg\u002Fm2 at screening and\n4. Unintentional weight gain of \\>10% from baseline (prior to INSTI initiation) within 1-3 years of starting INSTI ART, with no other apparent medical reason to explain the weight gain (concomitant medication use, Cushing's disease, recent prolonged hospitalization, etc.), in the opinion of the site investigator.\n5. Body fat percentage \\>20%\n6. No indication or plans to add or change medications associated with significant weight change during the study period.\n7. Participants currently receiving antipsychotics, antidepressants, anticonvulsants\u002Fmood stabilizers, and thyroid replacement hormones without dose modifications for at least 12 weeks prior to randomization\n8. Participants currently receiving antidiabetics known to cause weight loss and without dose modifications for at least 24 weeks prior to randomization (GLP-1 receptor agonists, SGLT-2 inhibitors, insulin, metformin).\n9. Agree to adhere to assigned ART during the study period\n10. HIV-1 RNA screening \\<50 copies\u002FmL performed within 45 days prior to study entry.\n11. GFR by CDK-EPI ≥60 mL\u002Fmin\n12. Alanine aminotransferase (ALT) and asparatate aminotransferase (AST) \\< 90 IU\u002FL\n13. Thyroid profile (TSH, free T3 and free T4) prior to entering the study\n14. Serum and urinary electrolytes, cystatin C, prior to entering the study\n\nExclusion Criteria:\n\n1. Loss of social security\n2. Allergy to any of the components of ART, previously unknown.\n3. Withdrawal of informed consent\n4. Acquiring HBV and\u002For HCV infection during follow-up.\n5. HIV-1 RNA \\>200 copies\u002FmL in 2 consecutive determinations after having achieved virological suppression.\n6. Early initiation or discontinuation of any of the following drugs after entering the study: antipsychotics (clozapine, olanzapine, risperidone); antidepressants (tricyclic antidepressants, selective serotonin reuptake inhibitors) monoamine oxidase inhibitors, associated with weight gain; anticonvulsants\u002Fmood stabilizers (lithium, valproic acid) or associated with weight loss (topiramate); thyroid replacement hormones;\n7. Change in dose or discontinuation of antidiabetic drugs that cause weight loss (GLP-1 receptor agonists, SGLT-2 inhibitors, insulin, metformin), after entering the study.\n8. Planning to undergo or having undergone bariatric surgery.\n9. Initiating significant dietary changes, advised by a nutritionist according to what was reported by the participant\n10. Initiating or increasing physical exercise or enrolling in a structured weight loss regimen: \\<250 minutes\u002Fweek of moderate to intense activity","MALE","18 Years","80 Years",{"count":21,"type":22},108,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Patients who developed metabolic syndrome after initiation of HIV treatment or with antiretroviral therapy (ART) for at least 36 months, treated with second generation integrase inhibitors (BIC\u002FTAF\u002FFTC, DTG\u002FABC\u002F3Tc or DTG+TDF\u002FFTC) who have gained at least 10% of their total body weight after starting ART, with a body mass index ≥25 kg\u002Fm2 and body fat greater than 20% will be eligible to participate in this clinical trial. If they decide to participate, they will sign an informed consent. After this, a mobile application will randomly decide whether the participant will continue with their ART regimen or switch to another ART (listed in the guidelines as one of the main lines of treatment) containing doravirine\u002Flamivudine\u002Fdisoproxil fumarate tenofovir. Medical visits will be at 1 month, 3 months, 6 months, 9 months, and 12 months after get in to this protocol, with laboratory studies that evaluate fats, blood sugar, liver function, kidney function, and test for HIV control; in addition, each visit will be given self-fillable scales to evaluate neuropsychiatric disorders such as depression, anxiety, insomnia, satisfaction with treatment or symptoms associated with it.The aim of the study is to observe whether there is weight loss with the change in HIV treatment.",[28,29,30,31,32,33],"HIV","HIV Associate Weight Loss","HIV-1 Infection","Integrase Inhibitors, HIV; HIV PROTEASE INHIB","Weight Change","Weight Loss",[28,35,36,37,38],"Integrase inhibitors","doravirine","Body Mass Index","Body Weight Changes","RECRUITING","2024-09-17",{"date":42,"type":43},"2024-09-19","ACTUAL",{"date":45,"type":43},"2024-08-14",{"date":47,"type":22},"2025-11-14",{"name":49,"class":50},"Instituto Mexicano del Seguro Social","OTHER_GOV",2]